- Home
- BMI vs CRNX Comparison
BMI vs CRNX Comparison
Compare BMI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$145.14
HOLD
Current Price
$44.75
Company Overview
Basic Information| Metric | BMI | CRNX |
|---|---|---|
| Founded | 1905 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMI | CRNX |
|---|---|---|
| Price | $145.14 | $44.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $193.14 | $75.78 |
| AVG Volume (30 Days) | 467.9K | ★ 1.3M |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 13.24 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $916,663,000.00 | $1,535,000.00 |
| Revenue This Year | $10.62 | $499.13 |
| Revenue Next Year | $5.82 | $893.14 |
| P/E Ratio | $30.54 | ★ N/A |
| Revenue Growth | 10.90 | ★ 47.74 |
| 52 Week Low | $139.14 | $24.10 |
| 52 Week High | $256.08 | $57.99 |
Technical Indicators
Market Signals| Indicator | BMI | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 32.09 |
| Support Level | $139.14 | $50.84 |
| Resistance Level | $153.30 | $50.57 |
| Average True Range (ATR) | 6.76 | 2.32 |
| MACD | -1.89 | -1.16 |
| Stochastic Oscillator | 16.74 | 2.14 |
Price Performance
Historical Comparison BMI
CRNX
About BMI Badger Meter Inc.
Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has global operations, with the vast majority of revenue derived from the US.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.